Adenocarcinoma of the small intestine mistaken as a primary ovarian cancer

Andresen, Deborah; Pedersen, Frants; Rasmussen, Kirsten

doi:10.1007/s004040000155

Cited by 8 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PubMed database was searched for literature on ovarian metastasis from small bowel cancer from January 1990 to September 2023, using the following search terms: (small bowel cancer) OR (small intestine cancer) OR (jejunum cancer) OR (duodenum cancer) OR (ileum cancer) AND (metastatic ovarian cancer). Only English-language literature were selected for documented case reports of ovarian metastases from SBA and there were 10 cases (Table II) (9)(10)(11)(12)(13)(14)(15)(16)(17)(18). There are some differences between this case and cases in Table II.…”

Section: Discussionmentioning

confidence: 99%

Non‑synchronous bilateral metastatic ovarian cancer originating from small bowel adenocarcinoma with multidisciplinary treatment: A case report

He,

Chen,

Zhou

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

Primary small bowel adenocarcinoma (SBA) is a rare gastrointestinal cancer with a low incidence of ovarian metastasis. Differential diagnosis of metastatic and primary ovarian cancer is often challenging. The present study reported the case of a 45-year-old woman with jejunal adenocarcinoma who presented with right ovarian, left ovarian, abdominopelvic implant and local recurrent bowel wall metastases successively after primary tumor resection. The ovarian masses of the patient originated from SBA, which was confirmed by immunohistochemical results. Following four comprehensive evaluations by an experienced multidisciplinary team (MDT) during the disease period, the patient underwent four operations, 28 cycles of chemotherapy, 24 cycles of targeted therapy and maintenance therapy for 8 months. As of February 2023, the patient has survived for 73 months and has a high quality of life. It is suggested that when a patient with SBA presents with an ovarian mass, the differential diagnosis between metastatic ovarian cancer and primary ovarian cancer mainly relies on immunohistochemistry. After a comprehensive evaluation by an experienced MDT, surgical resection is the primary treatment for advanced SBA, thus demonstrating some benefits for patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Non‑synchronous bilateral metastatic ovarian cancer originating from small bowel adenocarcinoma with multidisciplinary treatment: A case report

He,

Chen,

Zhou

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Many factors play major role in the disease development and these includes advance age (8,9), genetics associations (10)(11)(12), early menstruation (13), late menopausal age (14) and hormonal therapy (15). An ovarian tumor mainly originates from its own tissue but some multiple tumors such as colon (16), stomach (17), small intestine (18), pancreas (6), breast (19) and even thyroid cancer (20) can be metastasis to the ovary. The world health organization (WHO) classified the ovarian cancer histologically to many types based on their histological principles (21), the high grade serous ovarian carcinoma are considered the most common histological type (22).…”

Section: Introductionmentioning

confidence: 99%

The Response of Second Line Chemotherapy Platinum Resistant Ovarian Cancer in Sudan: 2013-2017

Alshykh

Essa

Suleiman

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Ovarian carcinoma is the fifth leading cause of cancer death worldwide. The tumor mostly associated with variant factors such as advance age, early menstruation and gene association. We aimed to highlight the effectiveness of the second line chemotherapy in the management of ovarian cancer patients in Sudan. Methods The data were collected from the hospital patient’s records for five years period of time, included 62 patients with ovarian cancer who is treated by the second line platinum resistant chemotherapy. Result The peak prevalence of the patients was found in Aljazeera state, and the least in Algadarif state. Age group above 55 years was the most affected group. The vast majority of patients showed partially mass disappearing, completes and continue growing tumor respectively. All patients received variant cycles of chemotherapy as fellow 3, 6, 2, 4, 5, 1 cycle respectively. 79.4% of the patients had achieved the normal value of cancer antigen 125 (CA125) levels after the treatment. 50% of patients had 1-2 months interval time before the cancer recurrence, 32.2% had 3-4 months and 17.8% had 5-6 months before the disease recurrence. The serous adenocarcinoma was found to be the most histological type in all the patients and the least two types were observed are cell carcinoma and serous papillary. Conclusion Our findings suggested that, Aljazeera state citizens were more vulnerable to resist the first line chemotherapy than others. The Sudanese patients with ovarian cancer may have better response to Gemzar.

show abstract

“…Many factors play major role in the disease development and these includes advance age (8,9), genetics associations (10)(11)(12), early menstruation (13), late menopause (14) and hormonal therapy (15). An ovarian tumors are mainly primary but secondaries from colon (16), stomach (17), small intestine (18), pancreas (6), breast (19) and even thyroid cancer (20) are also common. The world health organization (WHO) classified the ovarian cancer to many types based on their histological principles (21), the high grade serous ovarian carcinoma are considered the most common type (22).…”

Section: Introductionmentioning

confidence: 99%

The Response of Second Line Chemotherapy Platinum Resistant Ovarian Cancer in Sudan: 2013-2017

Alshykh

Essa

Suleiman

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Ovarian carcinoma is the fifth leading cause of cancer death worldwide. The tumor mostly associated with variant factors such as advance age, early menstruation and gene association. We aimed to highlight the effectiveness of the second line chemotherapy in the management of ovarian cancer patients in Sudan.Methods The data were collected from the hospital patient’s records for five years period of time, included 62 patients with ovarian cancer who is treated by the second line platinum resistant chemotherapy.Result The peak prevalence of the patients was found in Al-Gazeera state, and the least in Al-Gadarif state. Age group above 55 years was the most affected group. The vast majority of patients showed partially mass disappearing, completes and continue growing tumor respectively. All patients received variant cycles of chemotherapy as fellow 3, 6, 2, 4, 5, 1 cycle respectively. 79.4% of the patients had achieved the normal value of cancer antigen 125 (CA125) levels after the treatment. In 50% of patients the cancer recurred after 1-2 months, 32.2% after 3-4 months and 17.8% after 5-6 months. The serous adenocarcinoma was found to be the most histological type in all the patients and the least two types were observed are cell carcinoma and serous papillary.Conclusion Our findings suggested that, Al-Gazeera state citizens were more vulnerable to resist the first line chemotherapy than others. The Sudanese patients with ovarian cancer may have better response to Gemzar.

show abstract

Adenocarcinoma of the small intestine mistaken as a primary ovarian cancer

Cited by 8 publications

References 4 publications

Non‑synchronous bilateral metastatic ovarian cancer originating from small bowel adenocarcinoma with multidisciplinary treatment: A case report

Non‑synchronous bilateral metastatic ovarian cancer originating from small bowel adenocarcinoma with multidisciplinary treatment: A case report

The Response of Second Line Chemotherapy Platinum Resistant Ovarian Cancer in Sudan: 2013-2017

The Response of Second Line Chemotherapy Platinum Resistant Ovarian Cancer in Sudan: 2013-2017

Contact Info

Product

Resources

About